Novel antitumor 2-cyanoaziridine-1-carboxamides

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Novel anticancer agents are needed to overcome drug resistance in solid and hematological tumors.
• Aziridine derivatives have shown promise as cytotoxic agents.
• Imexon, a cyclized 2-cyanoaziridine-1-carboxamide, is of clinical interest.

Purpose of the Study:

• To synthesize and evaluate a series of 2-cyanoaziridine-1-carboxamide compounds.
• To assess their in vitro anticancer activity against various tumor cell lines.
• To investigate the structure-activity relationship, particularly the role of lipophilicity.

Main Methods:

• Synthesis of 20 2-cyanoaziridine-1-carboxamides from 2-cyanoaziridine and isocyanates.
• In vitro cytotoxicity assays against a panel of solid and hematological tumor cells.
• Evaluation of activity against drug-resistant cell lines (doxorubicin, mitoxantrone).
• Correlation analysis between compound lipophilicity and potency.
• Comparison with imexon against cloned fresh human tumors.

Main Results:

• All synthesized compounds exhibited activity against tested tumor cells.
• Compounds demonstrated efficacy against doxorubicin- and mitoxantrone-resistant strains.
• Potency strongly correlated with the lipophilicity of substituents.
• The N-phenyl derivative showed superior potency and comparable efficacy to imexon in human tumor assays.

Conclusions:

• 2-cyanoaziridine-1-carboxamides represent a promising class of anticancer agents.
• Lipophilicity is a key determinant of their cytotoxic activity.
• The N-phenyl derivative warrants further investigation as a potential therapeutic candidate.